MERZ PHARMACEUTICALS GMBH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1908-01-01

Employees: 101

Market Cap: -

Website: https://www.radiesse.de

Clinical Trials

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Phase 4

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Xeomin®

First Posted Date: 2011-12-06

Last Posted Date: 2022-10-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 283

Registration Number: NCT01486264

Locations: 🇺🇸
Merz Investigative Site #1256, New York, New York, United States
🇺🇸
Merz Investigative Site #001076, Boca Raton, Florida, United States
🇺🇸
Merz Investigative Site #001225, Loma Linda, California, United States

and more 40 locations

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Phase 3

Completed

Conditions: Post-stroke Spasticity of the Lower Limb

Interventions: Drug: IncobotulinumtoxinA (400 Units)
Drug: Placebo Comparator

First Posted Date: 2011-11-03

Last Posted Date: 2016-11-06

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 290

Registration Number: NCT01464307

Locations: 🇨🇿
Merz Investigational Site #420024, Ostrava-Poruba, Czech Republic
🇺🇸
Merz Investigational Site #001208, Long Beach, California, United States
🇨🇦
Merz Investigational Site #001204, Halifax, Nova Scotia, Canada

and more 50 locations

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

Phase 3

Completed

Conditions: Post-stroke Spasticity of the Upper Limb

Interventions: Drug: Placebo Comparator
Drug: IncobotulinumtoxinA (400 Units)

First Posted Date: 2011-07-12

Last Posted Date: 2017-01-16

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 317

Registration Number: NCT01392300

Locations: 🇺🇸
Merz Investigational Site # 001110, Overland Park, Kansas, United States
🇺🇸
Merz Investigational Site #001245, Chattanooga, Tennessee, United States
🇨🇿
Merz Investigational Site #420030, Praha, Czech Republic

and more 44 locations

Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3

Phase 4

Completed

Conditions: Nasolabial Folds
Physiological Stress
Disorder of Aging
Skin Diseases
Wrinkles

Interventions: Device: Hyaluronic Acid Filler

First Posted Date: 2011-02-28

Last Posted Date: 2011-06-20

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 40

Registration Number: NCT01305187

Locations: 🇩🇪
Praxisklinik Kaiserplatz, Frankfurt am Main, Germany

Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

Phase 2

Completed

Conditions: Subjective Cognitive Impairment
Memory, Concentration or Attention Problems
Retention Disorder, Cognitive
Memory Disorder

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2010-12-16

Last Posted Date: 2013-11-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 299

Registration Number: NCT01261741

Locations: 🇩🇪
Praxis Dr. Heidenreich, Böblingen, Germany
🇩🇪
Praxis Dr. Krause, Wolfratshausen, Germany
🇩🇪
Klinische Forschung Berlin-Mitte, Berlin-Mitte, Germany

and more 11 locations

Contractubex Treatment in Scars After Abdominal Caesarean Section

Phase 4

Completed

Conditions: Scars

Interventions: Drug: Contractubex

First Posted Date: 2010-04-28

Last Posted Date: 2014-04-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 61

Registration Number: NCT01112371

Locations: 🇲🇽
Jefe del Departamento Dermatologia, Facultad de medicina y Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey Nuevo León, C.p., Mexico

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

Phase 1

Completed

Conditions: Metabolism of Neramexane

Interventions: Drug: Neramexane

First Posted Date: 2010-04-23

Last Posted Date: 2011-02-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 8

Registration Number: NCT01109680

Locations: 🇧🇪
SGS Life Science Services, Antwerpen, Belgium

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2009-09-23

Last Posted Date: 2011-04-15

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 56

Registration Number: NCT00983099

Locations: 🇺🇸
California Clinical Trials, Glendale, California, United States

Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Neramexane

First Posted Date: 2009-09-17

Last Posted Date: 2011-02-15

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 126

Registration Number: NCT00978614

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2009-09-04

Last Posted Date: 2011-02-07

Lead Sponsor: Merz Pharmaceuticals GmbH

Registration Number: NCT00972127

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy